Project Grant R21HL175092
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$128K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
This $760,374 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports an integrative metabolomics study to identify diagnostic and prognostic blood signatures for pulmonary sarcoidosis. The study aims to incorporate single nucleotide polymorphisms (SNPs), gene expression, and plasma metabolomics/lipidomics to construct and validate predictive models for sarcoidosis diagnosis and progression....
This Project Grant award of $249,000 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify common and distinct metabolic and proteomic pathways associated with inflammation and fibrosis in pulmonary sarcoidosis. The research aims to use plasma samples from two studies to perform metabolomic and proteomic profiling, with the goal of defining molecular endotypes among pulmonary sarcoidosis patients and establishing a framework...
This federal Project Grant award of $751,954 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research into investigating CXCR3 blockade as a potential precision therapy for cardiac sarcoidosis. The principal investigator will utilize single-cell multi-omics and T-cell receptor sequencing to define the key pathogenic T-cell subsets and interactions between adaptive and innate immunity that drive cardiac...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $451,734 to The University of Iowa to conduct research on the role of residential bioaerosol exposure in pulmonary sarcoidosis. The project aims to determine the association between residential bioaerosol exposure and the severity of pulmonary sarcoidosis, investigate the impact of bioaerosol on immune dysregulation in fibrotic...
This $793,093 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program) supports research to define the regulatory landscape of systemic lupus erythematosus (SLE) and cardiovascular disease (CVD) comorbidity. The research team at the Oklahoma Medical Research Foundation, with a sub-award to the University of California, San Diego, will conduct systematic studies in macrophage cells to identify genetic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Oklahoma State University a $408,606 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to study the role of ERK1/2 signaling in SARS-CoV-2-induced dysregulated immunity and lung pathology. The 5-year project, which began on September 6, 2024, aims to demonstrate the critical role of myeloid cell TLR-ERK1/2 signaling in SARS-CoV-2-induced lung injury and pathology, investigate its impact on the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,061,189 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The research aims to study: 1) how epithelial cells regulate fibrosis and interact with myeloid cells, 2) mechanisms for impaired innate immunity against gram-positive infections in fibrosis, 3) delivery of cyclooxygenase inhibitors...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This federal Project Grant award, worth $827,356.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports a prospective study to determine the imaging response to immune suppressant therapy in patients with active cardiac sarcoidosis. The study aims to establish quantitative thresholds for imaging parameters, such as FDG uptake on PET and advanced cardiac MRI measures, that are associated with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...